

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/511,937
				Filing Date	(Intl.) April 24, 2003
				First Named Inventor	Jay WOHLGEMUTH
				Art Unit	1634
				Examiner Name	J. Martinell
Sheet	1	of	2	Attorney Docket Number	506612000104

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			
					T ⁶
1.	WO-97/16568-A1	05-09-1997	Bowie, L. J.		
2.	WO-00/58473-A2	10-05-2000	Curagen Corporation		
3.	WO-01/57182-A2	08-09-2001	Human Genome Sciences, Inc.		
4.	WO-02/057414-A2	07-25-2002	Biocardia, Inc.		

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	5.	DIETZ, A. B. et al. (2000). "Maturation of Human Monocyte-Derived Dendritic Cells Studied by Microarray Hybridization," <i>Biochemical and Biophysical Research Communications</i> 275:731-738.			
	6.	EMBL-EBI Accession No. AA053887, last updated August 31, 2006, located at < http://www.ebi.ac.uk/cgi-bin/dbfetch?db=embl&id=AA053887&style=raw > visited on October 31, 2007. (2 pages)			
	7.	EMBL-EBI Accession No. AAC77576, located at < http://www.ebi.ac.uk/cgi-bin/dbfetch?db=emblcds&id=AAC77576&style=raw > visited on October 31, 2007. (1 page).			
	8.	EMBL-EBI Accession No. AAK80490, located at < http://www.ebi.ac.uk/cgi-bin/dbfetch?db=emblcds&id=AAK80490&style=raw > visited on October 31, 2007. (1 page).			
	9.	EMBL-EBI Accession No. AI775145, last updated June 21, 2002, located at < http://www.ebi.ac.uk/cgi-bin/dbfetch?db=embl&id=AI775145&style=raw > visited on October 31, 2007. (2 pages).			
	10.	EMBL-EBI Accession No. AK000354, last updated September 12, 2006, located at < http://www.ebi.ac.uk/cgi-bin/dbfetch?db=embl&id=AK000354&style=raw > visited on October 31, 2007. (3 pages).			
	11.	EMBL-EBI Accession No. AV742425, last updated October 10, 2000, located at < http://www.ebi.ac.uk/cgi-bin/dbfetch?db=embl&id=AV742425&style=raw > visited on October 31, 2007. (2 pages).			
	12.	EMBL-EBI Accession No. AW969353, last updated June 8, 2000, located at < http://www.ebi.ac.uk/cgi-bin/dbfetch?db=embl&id=AW969353&style=raw > visited on October 31, 2007. (1 page).			
	13.	EMBL-EBI Accession No. G06338, last updated March 4, 2000, located at < http://www.ebi.ac.uk/cgi-bin/dbfetch?db=embl&id=G06338&style=raw > visited on October 31, 2007. (2 pages).			

Examiner Signature	/James Martinell/	Date Considered	03/13/2008
--------------------	-------------------	-----------------	------------

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/511,937
				Filing Date	(Intl.) April 24, 2003
				First Named Inventor	Jay WOHLGEMUTH
				Art Unit	1634
				Examiner Name	J. Martinell
Sheet	2	of	2	Attorney Docket Number	506612000104

	14.	EMBL-EBI Accession No. L26474, last updated January 9, 2007, located at <http://www.ebi.ac.uk/cgi-bin/dbfetch?db=embl&id=L26474&style=raw> visited on October 31, 2007. (6 pages).	
	15.	EMBL-EBI Accession No. M23068, last updated November 14, 2006, located at <http://www.ebi.ac.uk/cgi-bin/dbfetch?db=embl&id=M23068&style=raw> visited on October 31, 2007. (2 pages).	
	16.	EMBL-EBI Accession No. V00497, last updated November 20, 2004, located at <http://www.ebi.ac.uk/cgi-bin/dbfetch?db=embl&id=V00497&style=raw> visited on October 31, 2007. (5 pages).	
	17.	FINGER, L. R. et al. (1997). "The Human PD-1 Gene: Complete cDNA, Genomic Organization, and Developmentally Regulated Expression in B cell Progenitors," <i>Gene</i> 197:177-187.	
	18.	FULLERTON, S. M. et al. (March 1994). "Molecular and Population Genetic Analysis of Allelic Sequence Diversity at the Human Beta-Globin Locus," <i>Proceedings of the National Academy of Sciences</i> 91:1805-1809.	
	19.	GORCYNISKI, R. M. (1996). "Correlation of Peripheral Blood Lymphocyte and Intragraft Cytokine mRNA Expression with Rejection in Orthotopic Liver Transplantation," <i>Surgery</i> 120(3):496-502.	
	20.	GRIFFITHS, G. M. et al. (1991). "Granzyme A and Perforin as Markers for Rejection in Cardiac Transplantation," <i>European Journal of Immunology</i> 21:687-692.	
	21.	JARDI, M. et al. (1994). "Urokinase Receptor (UPAR) Expression During Hematopoietic Maturation," <i>Journal of Drug Targeting</i> 8(Suppl 1):51.	
	22.	JOULIN, V. et al. (October 25, 1988). "Isolation and Characterization of the Human 2,3-Bisphosphoglycerate Mutase Gene," <i>The Journal of Biological Chemistry</i> 263(30):15785-15790.	
	23.	KRAUSE, S. W. (1998). "Carboxypeptidase M as a Marker of Macrophage Maturation," <i>Immunological Reviews</i> 161:119-127.	
	24.	LE NAOUR, F. et al. (May 25, 2001). "Profiling Changes in Gene Expression during Differentiation and Maturation of Monocyte-Derived Dendritic Cells Using Both Oligonucleotide Microarrays and Proteomics," <i>The Journal of Biological Chemistry</i> 276(21):17920-17931.	
	25.	Supplementary European Search Report mailed October 18, 2007, for EP Application No. 03799755.8 filed April 24, 2003, 17 pages.	
	26.	TAMAYO, P. et al. (March 1999). "Interpreting Patterns of Gene Expression with Self-Organizing Maps: Methods and Application to Hematopoietic Differentiation," <i>Proceedings of the National Academy of Sciences</i> 96:2907-2912.	
	27.	WILLEMS, R. et al. (May 29, 1998). "Decrease in Nucleoside Diphosphate Kinase (NDPK/nm23) Expression During Hematopoietic Maturation," <i>The Journal of Biological Chemistry</i> 273(22):13663-13668.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/James Martinell/	Date Considered	03/13/2008
--------------------	-------------------	-----------------	------------

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/511,937
				Filing Date	(Intl.) April 24, 2003
				First Named Inventor	Jay WOHLGEMUTH
				Art Unit	1634
				Examiner Name	J. Martinell
Sheet	1	of	1	Attorney Docket Number	506612000104

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			
					<input type="checkbox"/> T ⁶

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			<input type="checkbox"/> T ²
	1.	DIETZ, A. B. et al. (2000). "Maturation of Human Monocyte-Derived Dendritic Cells Studied by Microarray Hybridization," <i>Biochemical and Biophysical Research Communications</i> 275:731-738.			
	2.	FINGER, L. R. et al. (1997). "The Human PD-1 Gene: Complete cDNA, Genomic Organization, and Developmentally Regulated Expression in B cell Progenitors," <i>Gene</i> 197:177-187.			
	3.	GORCZYNSKI, R. M. (1996). "Correlation of Peripheral Blood Lymphocyte and Intragraft Cytokine mRNA Expression with Rejection in Orthotopic Liver Transplantation," <i>Surgery</i> 120(3):496-502.			
	4.	KRAUSE, S. W. (1998). "Carboxypeptidase M as a Marker of Macrophage Maturation," <i>Immunological Reviews</i> 161:119-127.			
	5.	LE NAOUAR, F. et al. (May 25, 2001). "Profiling Changes in Gene Expression during Differentiation and Maturation of Monocyte-Derived Dendritic Cells Using Both Oligonucleotide Microarrays and Proteomics," <i>The Journal of Biological Chemistry</i> 276(21):17920-17931.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/James Martinell/	Date Considered	03/13/2008
--------------------	-------------------	-----------------	------------

sf- 2459991



3700

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

		Application Number	10/511,937
		Filing Date	April 24, 2003
		First Named Inventor	Jay WOHLGEMUTH
		Art Unit	3700
		Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	6+10 Refs.	Attorney Docket Number	506612000104

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	PTO/SB/08a/b Form - 2 pages 10 References Return Receipt Postcard
<input checked="" type="checkbox"/> Information Disclosure Statement (3 pages)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application	<input type="checkbox"/> Remarks	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	MORRISON & FOERSTER LLP, Customer No. 20872		
Signature			
Printed name	Otis Littlefield		
Date	2/10/06	Reg. No.	48,751

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 2/10/06 Signature: (Valerie Cohen)

O I P E 14P48
FEB 19 2006
PATENT & TRADEMARK OFFICE

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: February 10, 2006 Signature: Valerie Cohen
(Valerie Cohen)

Patent
Docket No. 506612000104

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Jay WOHLGEMUTH et al.

Serial No.: 10/511,937

Filing Date: April 24, 2003

For: METHODS AND COMPOSITIONS FOR
DIAGNOSING AND MONITORING
TRANSPLANT REJECTION

Examiner: Not Yet Assigned

Group Art Unit: 3700

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

This Supplemental Information Disclosure Statement is submitted:

- With the application; accordingly, no fee or separate requirements are required.
- Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.

- Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.**
- After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
- A fee is required. A check in the amount of __ is enclosed.
- A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
- A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is believed to be due.
- After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
- A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of __ is enclosed.
- A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.


The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including


extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket no. 506612000104.

Dated: February 10, 2006

Respectfully submitted,

By 
Otis Littlefield

Registration No.: 48,751
MORRISON & FOERSTER LLP
425 Market Street
San Francisco, California 94105-2482
(415) 268-6846



Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/511,937
				Filing Date	April 24, 2003
				First Named Inventor	Jay WOHLGEMUTH
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	506612000104

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			
1.	SG 200002150-0 WO02/057414A2	07-25-2002	Expression Diagnostics, Inc.		T ⁶

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	2.	Australian Search Report mailed October 7, 2005, for Singapore patent application no. SG 200406287-3, filed April 24, 2003, 2 pages			
	3.	BAKKE, Antony C. et al., (2001) "Neutrophil CD64 expression Distinguishing acute inflammatory autoimmune disease from systemic infections," Clinical and Applied Immunology Reviews, 1: 267-275			
	4.	DEUEL, Thomas F. et al., (June 1977) "Amino acid sequence of human platelet factor 4," Proc. Natl. Acad. Sci. USA, 74(6): 2256-2258			
	5.	DEUEL, Thomas F. et al., (July 1981) "Platelet factor 4 is chemotactic for neutrophils and monocytes," Proc. Natl. Acad. Sci. USA, 78(7): 4584-4587			
	6.	DUDEK, Arkadiusz Z. et al., (June 15, 2003) "Platelet factor 4 promotes adhesion of hematopoietic progenitor cells and binds IL-8: novel mechanisms for modulation of hematopoiesis," Blood, 101(12): 4687-4694			
	7.	GOLDEN-MASON, Lucy et al., (June 2000) "Differential Expression of Lymphoid and Myeloid Markers on Differentiating Hematopoietic Stem Cells in Normal and Tumor-Bearing Adult Human Liver," Hepatology, 31(6): 1251-1256			
	8.	MORRIS, Dale L. et al., (Feb. 1997) "Immunophenotyping Analysis of Peripheral Blood, Splenic, and Thymic Lymphocytes in Male and Female Rats," Journal of Pharmacological and Toxicological Methods,			

Examiner Signature	/James Martinell/	Date Considered	03/13/2008
--------------------	-------------------	-----------------	------------

sf- 2071335

Substitute for form 1449/PTO				<i>Complete if Known</i>	
				Application Number	10/511,937
				Filing Date	April 24, 2003
				First Named Inventor	Jay WOHLGEMUTH
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	506612000104

		37: 37-46	
	9.	SHIN, Young Kee et al., (April 2001) "Expression of Leukemia-Associated antigen, JL1, in Bone Marrow and Thymus," American Journal of Pathology, 158(4): 1473-1480	
	10.	STELLRECHT, Christine M. et al., (1991) "Expression pattern of a hematopoietic proteoglycan core protein gene during human hematopoiesis," Differentiation, 48: 127-135	


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/James Martinell/	Date Considered	03/13/2008
-----------------------	-------------------	--------------------	------------

sf-2071335

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JM/



3700

PTO/SB/21 (04-07)

Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM


(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission	5 + 14 Refs.	Application Number	10/511,937
		Filing Date	July 22, 2005
		First Named Inventor	Jay WOHLGEMUTH
		Art Unit	3700
		Examiner Name	Not Yet Assigned
		Attorney Docket Number	506612000104

ENCLOSURES (Check all that apply)


<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement (3 pages) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1. Form PTO/SB/08A/B (1 page) 2. Cited 14: Copies of 14 References Attached 3. Return Receipt Postcard
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	MORRISON & FOERSTER LLP (Customer No. 20872)		
Signature			
Printed name	Otis Littlefield		
Date	June 27, 2007	Reg. No.	48,751

I hereby certify that this paper is being deposited with the U.S. Postal Service on the date shown below in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: June 27, 2007

Signature:  (Valerie Cohen)

I hereby certify that this paper is being deposited with the U.S. Postal Service on the date shown below in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: June 27, 2007

Signature: Valerie Cohen (Valerie Cohen)

Patent

Docket No. 506612000104

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Jay WOHLGEMUTH et al.

Serial No.: 10/511,937

Filing Date: July 22, 2005

For: METHODS AND COMPOSITIONS FOR
DIAGNOSING AND MONITORING
TRANSPLANT REJECTION

Examiner: Not Yet Assigned

Group Art Unit: 3700

INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of foreign documents and non-patent literature are submitted herewith. This protocol conforms with 37 C.F.R. §1.98(d) and M.P.E.P. 609(A)(2). The Examiner is requested to make these documents of record in the application.

This Information Disclosure Statement is submitted:

- With the application; accordingly, no fee or separate requirements are required.
- Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.

- Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.**
- After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
- A fee is required. A check in the amount of __ is enclosed.
- A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
- A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is believed to be due.
- After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
- A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of __ is enclosed.
- A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other

fees due in connection with the filing of this document to **Deposit Account No. 03-1952**
referencing 506612000104.

Dated: June 27, 2007

Respectfully submitted,

By Otis Littlefield
Otis Littlefield

Registration No.: 48,751
MORRISON & FOERSTER LLP
425 Market Street
San Francisco, California 94105-2482
(415) 268-6846



Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	1	Attorney Docket Number	506612000104
-------	---	----	---	------------------------	--------------

Complete if Known

Application Number	10/511,937
Filing Date	July 22, 2005
First Named Inventor	Jay WOHLGEMUTH
Art Unit	3700
Examiner Name	Not Yet Assigned

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)	MM-DD-YYYY		

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
1.	WO-94/23023-A1		10-13-1994			
2.	WO-00/04191		01/2000			
3.	WO-00/12753		03/2000			
4.	WO-00/23573-A3		04/2000			
5.	WO-00/46372		08/2000			
6.	WO-00/52209		09/2000			
7.	WO-00/55375		09/2000			
8.	WO-00/63372		10/2000			
9.	WO-00/73498-A1		12/2000			
10.	WO-00/78808-A1		12/2000			
11.	WO-01/20004		03/2001			
12.	WO-01/23426		04/2001			
13.	WO-01/23564		04/2001			

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
14.	WEAST, Ed. (1968). <u>Handbook of Chemistry and Physics</u> , 49 th Ed., The Chemical Rubber Co.: Cleveland Ohio, pg. A-245.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/James Martinell/	Date Considered	03/13/2008
sf-2173585			

PATENT

DOCKET: 506612000104

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 990 375 635 US, in an envelope addressed to: **Commissioner for Patents, MAIL STOP: PCT/DO/EO/US, P.O. Box 1450, Alexandria, VA 22313-1450**, on the date shown below.

Dated: July 22, 2005

Signature: 

(LILIA OLSEN)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Jay WOHLGEMUTH et al.

Serial No.: 10/511,937

Filing Date: April 24, 2003 (PCT/US03/12946)
For:

METHODS AND COMPOSITIONS FOR
DIAGNOSING AND MONITORING
TRANSPLANT REJECTION

Examiner: Not Yet Assigned

Group Art Unit: Not Yet Assigned

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

MS: PCT/DO/EO/US
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of the documents were previously submitted in an Information Disclosure Statement and/or Office Action, directed to the related applications, Serial Number Nos. 10/131,831 filed April 24, 2002 and 10/325,899 filed December 20, 2002, and, accordingly, copies are not included herewith. This

protocol conforms with 37 C.F.R. §1.98(d) and M.P.E.P. 609(A)(2). The Examiner is requested to make these documents of record in the application.

This Information Disclosure Statement is submitted:

- With the application; accordingly, no fee or separate requirements are required.
- Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.**
- After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - A fee is required. A check in the amount of __ is enclosed.
 - A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is believed to be due.
- After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of __ is enclosed.
 - A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist;

(iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petitions for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing **506612000104**. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: July 22, 2005

Respectfully submitted,

By Michael R. Ward
Michael R. Ward
Registration No.: 38,651
MORRISON & FOERSTER LLP
425 Market Street
San Francisco, California 94105
(415) 268-6237

Substitute for form 1449/PTO				<i>Complete if Known</i>	
				Application Number	10/511,937
				Filing Date	April 24, 2003
				First Named Inventor	Jay WOHLGEMUTH
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	1	of	16	Attorney Docket Number	506612000104

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
1.	4,190,535		2/26/1980	Luderer et al.	
2.	4,350,593		9/21/1982	Kessler	
3.	4,358,535		11/9/1982	Falkow et al.	
4.	4,582,789		4/15/1986	Sheldon, III et al.	
5.	4,683,195		7/28/1987	Mullis et al.	
6.	4,683,202		7/28/1987	Mullis	
7.	4,751,001		6/14/1988	Saunders	
8.	4,762,780		8/9/1988	Spector et al.	
9.	4,789,630		12/6/1988	Bloch et al.	
10.	4,800,159		1/24/1989	Mullis et al.	
11.	4,818,418		4/4/1989	Saunders	
12.	4,843,155		6/27/1989	Chomczynski	
13.	4,889,818		12/26/1989	Gelfand et al.	
14.	4,908,318		3/13/1990	Lerner	
15.	4,946,952		8/7/1990	Kiefer	
16.	4,965,188		10/23/1990	Mullis et al.	
17.	5,053,134		10/1/1991	Luderer et al.	
18.	5,063,162		11/5/1991	Kiefer	
19.	5,066,584		11/19/1991	Gyllensten et al.	
20.	5,075,216		12/24/1991	Innis et al.	
21.	5,079,352		1/7/1992	Gelfand et al.	
22.	5,091,310		2/25/1992	Innis	
23.	5,142,033		8/25/1992	Innis	
24.	5,143,854		9/1/1992	Pirrung et al.	
25.	5,210,015		5/11/1993	Gelfand et al.	
26.	5,212,071		5/18/1993	Fearon et al.	
27.	5,215,882		6/1/1993	Bahl et al.	
28.	5,219,727		6/15/1993	Wang et al.	

Examiner Signature	/James Martineil/	Date Considered	03/13/2008
--------------------	-------------------	-----------------	------------

sf-1835832

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JM/

Substitute for form 1449/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/511,937
<i>(Use as many sheets as necessary)</i>				Filing Date	April 24, 2003
				First Named Inventor	Jay WOHLGEMUTH
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	2	of	16	Attorney Docket Number	506612000104

29.	5,264,351	11/23/1993	Harley	
30.	5,278,043	1/11/1994	Bannwarth et al.	
31.	5,310,652	5/10/1994	Gelfand et al.	
32.	5,314,809	5/24/1994	Erlich et al.	
33.	5,322,770	6/21/1994	Gelfand	
34.	5,340,720	08/23/1994	Stetler	
35.	5,352,600	10/4/1994	Gelfand et al.	
36.	5,374,553	12/20/1994	Gelfand et al.	
37.	5,385,824	1/31/1995	Hoet et al.	
38.	5,389,512	2/14/1995	Sninsky et al.	
39.	5,393,672	2/28/1995	Van Ness et al.	
40.	5,405,774	4/11/1995	Abramson et al.	
41.	5,407,800	4/18/1995	Gelfand et al.	
42.	5,411,876	5/2/1995	Bloch et al.	
43.	5,418,149	5/23/1995	Gelfand et al.	
44.	5,420,029	5/30/1995	Gelfand et al.	
45.	5,455,170	8/29/1995	Abramson et al.	
46.	5,445,940	10/3/1995	Brenner et al.	
47.	5,459,037	10/17/1995	Sutcliffe et al.	
48.	5,466,591	11/14/1995	Abramson et al.	
49.	5,468,613	11/21/1995	Erlich et al.	
50.	5,476,774	12/19/1995	Wang et al.	
51.	5,487,970	1/30/1996	Rowley et al.	
52.	5,487,972	1/30/1996	Gelfand et al.	
53.	5,491,063	2/13/1996	Fisher et al.	
54.	5,491,086	2/13/1996	Gelfand et al.	
55.	5,501,963	3/26/1996	Burckhardt	
56.	5,512,462	4/30/1996	Cheng	
57.	5,514,556	5/7/1996	Shearer et al.	
58.	5,538,848	7/23/1996	Livak et al.	

Examiner Signature	/James Martineil/	Date Considered	03/13/2008
-----------------------	-------------------	--------------------	------------

sf-1835832

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JM/

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/511,937
				Filing Date	April 24, 2003
				First Named Inventor	Jay WOHLGEMUTH
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	3	of	16	Attorney Docket Number	506612000104

59.	5,561,058	10/1/1996	Gelfand et al.	
60.	5,565,339	10/15/1996	Bloch et al.	
61.	5,569,583	10/29/1996	Greenberg et al.	
62.	5,571,673	11/5/1996	Picone	
63.	5,573,906	11/12/1996	Bannworth et al.	
64.	5,604,099	2/18/1997	Erlich et al.	
65.	5,618,703	4/8/1997	Gelfand et al.	
66.	5,618,711	4/8/1997	Gelfand et al.	
67.	5,624,833	4/29/1997	Gelfand et al.	
68.	5,635,365	6/3/1997	Ansari et al.	
69.	5,641,864	6/24/1997	Gelfand	
70.	5,658,744	8/19/1997	Ochoa et al.	
71.	5,665,551	9/9/1997	Gelfand et al.	
72.	5,674,738	10/7/1997	Abramson et al.	
73.	5,677,152	10/14/1997	Birch et al.	
74.	5,693,517	12/2/1997	Gelfand et al.	
75.	5,707,807	1/13/1998	Kato	
76.	5,716,787	2/10/1998	Dunn et al.	
77.	5,721,351	2/24/1998	Levinson	
78.	5,766,585	6/16/1998	Evans et al.	
79.	5,773,258	6/30/1998	Birch et al.	
80.	5,789,224	8/4/1998	Gelfand et al.	
81.	5,795,762	8/18/1998	Abramson et al.	
82.	5,804,375	9/8/1998	Gelfand et al.	
83.	5,807,522	9/15/1998	Brown et al.	
84.	5,811,284	9/22/1998	Chang et al.	
85.	5,837,832	11/17/1998	Chee et al.	
86.	5,939,270	8/17/1999	Haunsø et al.	
87.	5,939,292	8/17/1999	Gelfand et al.	
88.	5,958,342	9/28/1999	Gamble et al.	

Examiner Signature	/James Martineil/	Date Considered	03/13/2008
--------------------	-------------------	-----------------	------------

sf- 1835832

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JM/

Substitute for form 1449/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/511,937
<i>(Use as many sheets as necessary)</i>				Filing Date	April 24, 2003
				First Named Inventor	Jay WOHLGEMUTH
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	4	of	16	Attorney Docket Number	506612000104

89.	5,958,688	9/28/1999	Eberwine et al.	
90.	5,965,366	10/12/1999	Ochoa et al.	
91.	5,968,799	10/19/1999	Gelfand et al.	
92.	5,973,137	10/26/1999	Heath	
93.	5,981,481	11/9/1999	Fearon et al.	
94.	5,994,056	11/30/1999	Higuchi	
95.	5,994,076	11/30/1999	Chenchik et al.	
96.	6,001,611	12/14/1999	Will	
97.	6,004,755	12/21/1999	Wang	
98.	6,010,853	1/4/2000	Kanteti et al.	
99.	6,020,186	2/1/2000	Henco et al.	
100.	6,033,860	3/7/2000	Lockhart et al.	
101.	6,040,138	3/21/2000	Lockhart et al.	
102.	6,040,166	3/21/2000	Erlich et al.	
103.	6,045,996	4/04/2000	Cronin et al.	
104.	6,048,695	4/11/2000	Bradley et al.	
105.	6,048,709	4/11/2000	Falb	
106.	6,060,240	5/9/2000	Kamb et al.	
107.	6,066,322	5/23/2000	Levinson	
108.	6,066,498	5/23/2000	Levinson	
109.	6,084,083	7/4/2000	Levinson	
110.	6,087,112	7/11/2000	Dale	
111.	6,087,477	7/11/2000	Falb et al.	
112.	6,090,556	7/18/2000	Kato	
113.	6,099,823	8/8/2000	Falb	
114.	6,124,433	9/26/2000	Falb et al.	
115.	6,127,155	10/3/2000	Gelfand et al.	
116.	6,146,828	11/14/2000	Lapidus et al.	
117.	6,150,121	11/21/2000	Hamawy et al.	

Examiner Signature	/James Martineil/	Date Considered	03/13/2008
-----------------------	-------------------	--------------------	------------

sf-1835832

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JM/

Substitute for form 1449/PTO				<i>Complete if Known</i>	
				Application Number	10/511,937
				Filing Date	April 24, 2003
				First Named Inventor	Jay WOHLGEMUTH
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	5	of	16	Attorney Docket Number	506612000104

118.	6,156,887	12/5/2000	Levinson	
119.	6,162,604	12/19/2000	Jacob	
120.	6,168,933 B1	1/2/2001	Kaser et al.	
121.	6,171,785 B1	1/9/2001	Higuchi	
122.	6,177,254 B1	1/23/2001	Rattner et al.	
123.	6,187,534 B1	2/13/2001	Strom et al.	
124.	6,190,857 B1	2/20/2001	Ralph et al.	
125.	6,190,872 B1	2/20/2001	Slotman	
126.	6,194,158 B1	2/27/2001	Kroes et al.	
127.	6,197,563 B1	3/6/2001	Erlich et al.	
128.	6,204,371 B1	3/20/2001	Levinson	
129.	6,214,979 B1	4/10/2001	Gelfand et al.	
130.	6,218,122 B1	4/17/2001	Friend et al.	
131.	6,225,084 B1	5/1/2001	Falb et al.	
132.	6,225,093 B1	5/1/2001	Grant et al.	
133.	6,228,628 B1	5/8/2001	Gelfand et al.	
134.	6,242,185 B1	6/5/2001	Kaser et al.	
135.	6,245,334 B1	6/12/2001	Seilhammer et al.	
136.	6,245,526 B1	6/12/2001	Yue et al.	
137.	6,245,527 B1	6/12/2001	Busfield et al.	
138.	6,248,527 B1	6/19/2001	Chen et al.	
139.	6,248,528 B1	6/19/2001	Chen et al.	
140.	6,251,597 B1	6/26/2001	Shyjan	
141.	6,262,244 B1	7/17/2001	Houchins et al.	
142.	6,274,312 B1	8/14/2001	Gish et al.	
143.	6,280,941 B1	8/28/2001	Tsao et al.	
144.	6,303,321 B1	10/16/2001	Tracey et al.	
145.	6,306,602 B1	10/23/2001	Sillekens et al.	
146.	6,365,352 B1	4/2/2002	Yerramilli, et al.	
147.	6,403,304 B1	6/11/2002	Stashenko et al.	
148.	6,410,319 B1	6/25/2002	Raubitschek et al.	

Examiner Signature	/James Martineil/	Date Considered	03/13/2008
-----------------------	-------------------	--------------------	------------

sf-1835832

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JM/

Substitute for form 1449/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/511,937
Sheet	6	of	16	Filing Date	April 24, 2003
				First Named Inventor	Jay WOHLGEMUTH
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	506612000104

	149.	2002/0042386 A1	4/11/2002	Rosen et al.	
	150.	2002/0128436 A1	9/12/2002	Strom et al.	
	151.	2002/0132235 A1	9/19/2002	Avihingsanon et al.	
	152.	2004/0033498 A1	2/19/2004	Behrens et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			
	153.	EP 0 217 102 A2	4/8/1987		
	154.	EP 0 217 992 A2	4/15/1987		
	155.	EP 1 077 254 A2	2/12/2001		
	156.	EP 1 162 276 A2	12/12/2001		
	157.	WO 91/18626	12/12/1991		
	158.	WO 95/17506	6/29/1995		
	159.	WO 96/39536	12/12/1996		
	160.	WO 97/30065	8/21/1997		
	161.	WO 98/24935	6/11/1998		
	162.	WO 99/10536	3/4/1999		
	163.	WO 99/11782	3/11/1999		
	164.	WO 99/15700	4/1/1999		
	165.	WO 99/52541	10/21/1999		
	166.	WO 99/57130	11/11/1999		
	167.	WO 00/04191	1/27/2000		
	168.	WO 00/12753	3/9/2000		
	169.	WO 00/23573	4/27/2000		
	170.	WO 00/46372	8/10/2000		
	171.	WO 00/52209	9/8/2000		
	172.	WO 00/55375	9/21/2000		
	173.	WO 00/63372	10/26/2000		
	174.	WO 00/73498	12/07/2000		
	175.	WO 00/78808	12/28/2000		
	176.	WO 01/20004	3/22/2001		

Examiner Signature	/James Martineil/	Date Considered	03/13/2008
--------------------	-------------------	-----------------	------------

sf- 1835832

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JM/

Substitute for form 1449/PTO				<i>Complete if Known</i>	
				Application Number	10/511,937
				Filing Date	April 24, 2003
				First Named Inventor	Jay WOHLGEMUTH
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	7	of	16	Attorney Docket Number	506612000104

	177.	WO 01/23426	4/5/2001			
	178.	WO 01/23564	4/5/2001			
	179.	WO 01/25473	4/12/2001			
	180.	WO 01/29269	4/26/2001			
	181.	WO 01/32927	5/10/2001			
	182.	WO 01/40302 A2	6/7/2001			
	183.	WO 01/47944 A2	7/5/2001			
	184.	WO 01/54733 A1	8/2/2001			
	185.	WO 01/55164 A1	8/2/2001			
	186.	WO 01/55201 A1	8/2/2001			
	187.	WO 01/55203 A1	8/2/2001			
	188.	WO 01/55205 A1	8/2/2001			
	189.	WO 01/55328 A2	8/2/2001			
	190.	WO 01/55368 A1	8/2/2001			
	191.	WO 01/60860 A3	8/23/2001			
	192.	WO 01/71005 A2	9/27/2001			
	193.	WO 01/81916 A2	11/01/2001			
	194.	WO 01/86003 A2	11/15/2001			
	195.	WO 02/00677 A1	1/3/2002			
	196.	WO 02/00928 A2	1/3/2002			
	197.	WO 02/28999 A2	4/11/2002			

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				²
	198.	International Search Report mailed on September 30, 2004, for PCT patent application no. PCT/US03/13015, 4 pages.				

Examiner Signature	/James Martineil/	Date Considered	03/13/2008
--------------------	-------------------	-----------------	------------

sf- 1835832

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JM/

Substitute for form 1449/PTO				<i>Complete if Known</i>	
				Application Number	10/511,937
				Filing Date	April 24, 2003
				First Named Inventor	Jay WOHLGEMUTH
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	8	of	16	Attorney Docket Number	506612000104

	199.	Abdallah, A. N. et al. (1997) "Evaluation of plasma levels of tumour necrosis factor alpha and interleukin-6 as rejection markers in a cohort of 142 heart-grafted patients followed by endomyocardial biopsy" <i>European Heart Journal</i> 18: 1024-1029.	
	200.	Ajjan, R. A. et al. (1996) "Intrathyroidal cytokine gene expression in Hashimoto's thyroiditis" <i>Clin. Exp. Immunol.</i> 105: 523-528.	
	201.	Akalin, Enver et al. (2001) "Gene Expression Analysis in Human Renal Allograft Biopsy Samples Using High-Density Oligoarray Technology" <i>Transplantation</i> 72 (5): 948-953.	
	202.	Alizadeh, A. A. et al. (2000) "Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling" <i>Nature</i> 403: 503-11.	
	203.	Alizadeh, A. et al. (1998) "Probing Lymphocyte Biology by Genomic-Scale Gene Expression Analysis" <i>J. Clin. Immun.</i> 18: 373-379.	
	204.	Alizadeh, A. et al. (1999) "The Lymphochip: A Specialized cDNA Microarray for the Genomic-scale Analysis of Gene Expression in Normal and Malignant Lymphocytes" <i>Cold Spring Harbor Symposia on Quantitative Biology</i> 54, (New York: Cold Spring Harbor Laboratory Press): 71- 78.	
	205.	Alpert, Susan et al. (1995) "The Relationship of Granzyme A and Perforin Expression to Cardiac Allograft Rejection and Dysfunction" <i>Transplantation</i> 60 (12): 1478-1485.	
	206.	Arnett, F. C. et al. (1988) "The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis" <i>Arthritis Rheum</i> 31: 315-24.	
	207.	Autieri MV, Kelemen S, Thomas BA, Feller ED, Goldman BI, Eisen HJ. (2002) "Allograft inflammatory factor-1 expression correlates with cardiac rejection and development of cardiac allograft vasculopathy" <i>Circulation</i> 106(17):2218-23.	
	208.	Baechler, Emily C. et al. (2003) "Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus" <i>Proc. Natl. Acad. Sci. USA</i> 100 (5): 2610-2615.	
	209.	Bave, U. (2000) "The combination of apoptotic U937 cells and lupus IgG is a potent IFN-alpha inducer" <i>J. Immunol.</i> 165: 3519-3526.	
	210.	Bave, U. (2001) "Activation of natural interferon-alpha producing cells by apoptotic U937 cells combined with lupus IgG and its regulation by cytokines" <i>J. Autoimmun.</i> 17: 71-80.	

Examiner Signature	/James Martineil/	Date Considered	03/13/2008
--------------------	-------------------	-----------------	------------

sf-1835832

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JM/

Substitute for form 1449/PTO				<i>Complete if Known</i>	
				Application Number	10/511,937
				Filing Date	April 24, 2003
				First Named Inventor	Jay WOHLGEMUTH
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	9	of	16	Attorney Docket Number	506612000104

	211.	Bittner, M. et al. (2000) "Molecular classification of cutaneous malignant melanoma by gene expression profiling" <i>Nature</i> 406: 536-540.	
	212.	Bombardier, C. et al. and the Committee on Prognosis Studies in SLE (1992) "Derivation of the SLEDAI, A Disease Activity Index for Lupus Patients" <i>Arthritis Rheum.</i> 35: 630-640.	
	213.	Chang, D. M. et al. (1996) "Cytokines and Cell Surface Markers in Prediction of Cardiac Allograft Rejection" <i>Immunological Investigations</i> 25 (1&2): 13-21.	
	214.	Chebath et al. (1987) "Four Different Forms of Interferon-induced 2', 5'-Oligo(A) Synthetase Identified by Immunoblotting in Human Cells," <i>J. Biol. Chem.</i> 262: 3852-2857.	
	215.	Creemers P, Brink J, Wainwright H, Moore K, Shephard E, Kahn D. (2002) "Evaluation of peripheral blood CD4 and CD8 lymphocyte subsets, CD69 expression and histologic rejection grade as diagnostic markers for the presence of cardiac allograft rejection" <i>Transpl Immunol.</i> 10(4):285-92.	
	216.	Damas, J. K. et al. (2001) "Enhanced gene expression of chemokines and their corresponding receptors in mononuclear blood cells in chronic heart failure--modulatory effect of intravenous immunoglobulin" <i>J. Am. Coll. Cardiol.</i> 38: 187-93.	
	217.	Database Gen Embl, US National Library of Medicine (Bathesda, MD, USA), No. AL 591031, 'Human DNA sequence from clone RP11-151d14 on chromosome 9q13-21.2, complete sequence', Sycamore, N., 10 October, 2001.	
	218.	Davas, E.M. et al. (1999) "Serum IL-6, TNFalpha, p55 srTNFalpha, p75srTNFalpha, srIL-2alpha levels and disease activity in systemic lupus erythematosus" <i>Clin Rheumatol</i> 18 (1):17-22.	
	219.	Deng, Mario C. et al. (1995) "The Relation of Interleukin-6, Tumor Necrosis factor- α , IL-2, and IL-2 Receptor Levels to Cellular Rejection, Allograft Dysfunction, and Clinical Events Early After Cardiac Transplantation" <i>Transplantation</i> 60 (10): 1118-1124.	
	220.	Doi, S. et al. (1994) "Polymerase chain reaction quantification of cytokine messenger RNA expression in peripheral blood mononuclear cells of patients with acute exacerbations of asthma: effect of glucocorticoid therapy" <i>Clinical and Experimental Allergy</i> 24: 854-867.	

Examiner Signature	/James Martineil/	Date Considered	03/13/2008
--------------------	-------------------	-----------------	------------

sf-1835832

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JM/

Substitute for form 1449/PTO				<i>Complete if Known</i>	
				Application Number	10/511,937
				Filing Date	April 24, 2003
				First Named Inventor	Jay WOHLGEMUTH
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	10	of	16	Attorney Docket Number	506612000104

	221.	Dugré, Francine J. (2000) "Cytokine and Cytotoxic Molecule Gene Expression Determined in Peripheral Blood Mononuclear Cells in the Diagnosis of Acute Renal Rejection" <i>Transplantation</i> 70 (7): 1074-1080.	
	222.	Edman, C. F. et al. (1997) "Electric field directed nucleic acid hybridization on microchips" <i>Nucleic Acids Res.</i> 25: 4907-14.	
	223.	Eisen, Michael B. et al. (1998) "Cluster analysis and display of genome-wide expression patterns" <i>Proc. Natl. Acad. Sci. USA</i> 95: 14863-14868.	
	224.	Felson, D. T. et al. (1995) "American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis" <i>Arthritis Rheum.</i> 38: 727-35.	
	225.	Fu, Guoliang et al. (2002) "Representational difference analysis in a lupus-prone mouse strain results in the identification of an unstable region of the genome on chromosome 11" <i>Nucleic Acids Research</i> 30 (6): 1394-1400.	
	226.	Gabay C. et al. (1997) "Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity" <i>J Rheumatol</i> 24(2): 303-8.	
	227.	Ghosh et al. (2001) "A Specific Isozyme of 2'-5' Oligoadenylate Synthetase Is a Dual Function Proapoptotic Protein of the Bcl-2 Family," <i>J. Biol. Chem.</i> 276(27): 25477-25455.	
	228.	Golub, T. R. et al. (1999) "Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring" <i>Science</i> 286: 531-7.	
	229.	Grant, Simon C. D. et al. (1996) "Serum Cytokines in Human Heart Transplant Recipients" <i>Transplantation</i> 62 (4): 480-491.	
	230.	Gullestad, L. et al. (1999) "Effect of High- Versus Low-Dose Angiotensin Converting Enzyme Inhibition on Cytokine Levels in Chronic Heart Failure" <i>J. Am. Coll. Cardiol.</i> 34: 2061-7.	
	231.	Hastie, T. et al. (2000) "Gene shaving' as a method for identifying distinct sets of genes with similar expression patterns" <i>Genome Biol.</i> 1: RESEARCH0003.	
	232.	Hastie, Trevor et al. (2001) "Supervised harvesting of expression trees" <i>Genome Biology</i> 2 (1): http://genomebiology.com/2001/2/1/research/0003 (4/25/02): 12 pages.	

Examiner Signature	/James Martineil/	Date Considered	03/13/2008
--------------------	-------------------	-----------------	------------

sf- 1835832

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JM/

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/511,937
				Filing Date	April 24, 2003
				First Named Inventor	Jay WOHLGEMUTH
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	11	of	16	Attorney Docket Number	506612000104

233.	Heller, R. A. et al. (1997) "Discovery and analysis of inflammatory disease-related genes using cDNA microarrays" <i>Proc. Natl. Acad. Sci. U.S.A.</i> 94: 2150-2155.	
234.	Hendricks, DA et al. (1995) "Quantitation of HBV DNA in human serum using a branched DNA (bDNA) signal amplification assay" <i>Am J Clin Pathol</i> 104 (5): 537-46.	
235.	Higuchi et al. (1998), Chemical Abstracts 129: 342625: 7 pages.	
236.	Hooks, J.J. (1979) "Immune interferon in the circulation of patients with autoimmune disease" <i>N. Engl. J. Med.</i> 301: 5-8.	
237.	Hooks, J.J. et al. (1982) "Multiple interferons in the circulation of patients with systemic lupus erythematosus and vasculitis" <i>Arthritis Rheum.</i> 25: 396-400.	
238.	Hsieh, Hsian-Guey et al. (2001) "IL-17 expression as a possible predictive parameter for subclinical renal allograft rejection" <i>Transplant Int</i> 14: 287-298.	
239.	Iida, K. et al. (1982) "Complement receptor (CR1) deficiency in erythrocytes from patients with systemic lupus erythematosus" <i>J. Exp. Med.</i> 155: 1427-1438.	
240.	Jagota, Arun (2000) <u>Data Analysis and Classification for Bioinformatics</u> . Bioinformatics By The Bay Press: 92-93.	
241.	Kasprzycka, Monika et al. (2002) "Expression of FasL gene in T cells of renal allograft recipients" <i>Immunol. Lett.</i> 80 (1): 9-13.	
242.	Katz, Mitchell H (1999) <u>Multivariable Analysis: A Practical Guide for Clinicians</u> . Cambridge University Press: 36-42.	
243.	Khan, J. et al. (2001) "Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks" <i>Nat. Med.</i> 7: 673-9.	
244.	Kimball, P. et al. (1995) "Cytokine Panel Predicts Early Rejection of Therapeutic Response After Cardiac Transplantation" <i>Transplantation Proceedings</i> 27 (1): 1286-1287.	
245.	Kobashigawa, J. et al. (1998) "A Randomized Active-Controlled Trial of Mycophenolate Mofetil in Heart Transplant Recipients" <i>Transplantation</i> 66 (4): 507-515.	
246.	Kumar et al. (2000) "Expansion and Molecular Evolution of the Interferon-Induced 2'-5' Oligoadenylate Synthetase Gene Family," <i>Mol. Biol. Evol.</i> 17: 738-750.	

Examiner Signature	/James Martineil/	Date Considered	03/13/2008
--------------------	-------------------	-----------------	------------

sf- 1835832

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JM/

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/511,937
<i>(Use as many sheets as necessary)</i>				Filing Date	April 24, 2003
				First Named Inventor	Jay WOHLGEMUTH
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	12	of	16	Attorney Docket Number	506612000104

247.	Kumar et al. (1994) "Cell Cycle-dependent Modulation of α -Interferon-inducible Gene Expression and Activation of Signaling Components in Daudi Cells," <i>J. Biol. Chem.</i> 269, No. 41: 25437-25441.	
248.	Legros-Maida, Sabine et al. (1994) "Granzyme B and perforin can be used as predictive markers of acute rejection in heart transplantation" <i>Eur. J. Immunol.</i> 24: 229-233.	
249.	Li, B. et al. (2001) "Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine" <i>N. Engl. J. Med.</i> 344: 947-954.	
250.	Liossis, S.N. (2001) "B-cell kinase lyn deficiency in patients with systemic lupus erythematosus" <i>J Investig Med.</i> 49 (2): 157-65.	
251.	Loftus, B.J. et al. Genome Duplications and Other Features in 12 Mb of DNA sequence from Human Chromosome 16p and 16q Genomics. Vol. 60, pages 295-308 July 1999.	
252.	Magnusson, M. et al. (2001) "Importance of CpG dinucleotides in activation of natural IFN-alpha-producing cells by a lupus-related oligodeoxynucleotide" <i>Scand. J. Immunol.</i> 54: 543-550.	
253.	Marcelin, Anne-Genevieve et al. (2001) "Effects of Cyclosporine and Hydrocortisone on Kaposi's Sarcoma-Associated Herpesvirus Genome Replication and Cell Apoptosis Induction" <i>Transplantation</i> 72 (10): 1700-1708.	
254.	Melter, Michael et al. (2001) "Expression of the Chemokine Receptor CXCR3 and Its Ligand IP-10 During Human Cardiac Allograft Rejection" <i>Circulation</i> 104: 2558-2564.	
255.	Mohler, E. R. 3rd et al. "Role of Cytokines in the Mechanism of Action of Amlodipine: The PRAISE Heart Failure Trial" <i>J. Am. Coll. Cardiol.</i> 30 (1997): 35-41.	
256.	Morita, Ken et al. (2001) "Early Chemokine Cascades in Murine Cardiac Grafts Regulate T Cell Recruitment and Progression of Acute Allograft Rejection" <i>J. Immunol.</i> 167: 2979-2984.	
257.	Neto, E. D. et al. (2000). "Shotgun Sequencing of the Human Transcriptome with ORF Expressed Sequences Tags." <i>Proceedings of the National Academy of Sciences</i> , 97(7): 3491-3496.	
258.	Nickel, Peter et al. (2001) "Cytotoxic Effector Molecule Gene Expression in Acute Renal Allograft Rejection" <i>Transplantation</i> 72 (6): 1158-1161.	

Examiner Signature	/James Martineil/	Date Considered	03/13/2008
--------------------	-------------------	-----------------	------------

sf- 1835832

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JM/

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/511,937
				Filing Date	April 24, 2003
				First Named Inventor	Jay WOHLGEMUTH
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	13	of	16	Attorney Docket Number	506612000104

	259.	Oh, Se-Il et al. (2001) "Correlation of Fas and Fas Ligand Expression with Rejection Status of Transplanted Heart in Human" <i>Transplantation</i> 71 (7): 906-909.	
	260.	Perou, C. M. et al. (2000) "Molecular portraits of human breast tumours" <i>Nature</i> 406: 747-52.	
	261.	Preble, O.T. (1982) "Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon" <i>Science</i> 216: 429-431.	
	262.	Pruitt, K. D. et al. (2000) "Introducing RefSeq and LocusLink: curated human genome resources at the NCBI" <i>Trends Genet.</i> 16: 44-47.	
	263.	Raychaudhuri, S. et al. (2001) "Basic microarray analysis: grouping and feature reduction" <i>Trends Biotechnol.</i> 19: 189-193.	
	264.	Rebouillat et al. (1999) "The 100-kDa 2',5'-Oligoadenylate Synthase Catalyzing Preferentially the Synthesis of Dimeric pppA2'p5'A Molecules Is Composed of Three Homologous Domains" <i>J. Biol. Chem.</i> 274 (3): 1557-1565.	
	265.	Rus, V et al. (2002) "Expression of cytokine- and chemokine-related genes in peripheral blood mononuclear cells from lupus patients by cDNA array" <i>Clin Immunol</i> 102 (3): 283-90.	
	266.	Saiura, Akio et al. (2001) "A Comparison of Gene Expression in Murine Cardiac Allografts and Isografts by Means DNA Microarray Analysis" <i>Transplantation</i> 72 (2): 320-329.	
	267.	Salmon, J. E. et al. (1996) "Fc-gamma-RIIA alleles are heritable risk factors for lupus nephritis in African Americans" <i>J. Clin. Invest.</i> 97: 1348-1354.	
	268.	Schena, Mark et al. (1995) "Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray" <i>Science</i> 270: 467-470.	
	269.	Schena, Mark et al. (1996) "Parallel human genome analysis: Microarray-based expression monitoring of 1000 genes" <i>Proc. Natl. Acad. Sci. USA</i> 93: 10614-10619.	
	270.	Schowengerdt et al (2000) "Increased expression of the lymphocyte early activation marker CD69 in peripheral blood correlates with histologic evidence of cardiac allograft rejection." <i>Transplantation</i> 69(10):2102-7	
	271.	Sharma, Vijay K. et al. (1996) "Molecular Executors of Cell Death-Differential Intrarenal Expression of Fas Ligand, Fas, Granzyme B, and Perforin During Acute and/or Chronic Rejection of Human Renal Allografts" <i>Transplantation</i> 62 (12): 1860-1866.	

Examiner Signature	/James Martinelli/	Date Considered	03/13/2008
--------------------	--------------------	-----------------	------------

sf- 1835832

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JM/

Substitute for form 1449/PTO				<i>Complete if Known</i>	
				Application Number	10/511,937
				Filing Date	April 24, 2003
				First Named Inventor	Jay WOHLGEMUTH
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	14	of	16	Attorney Docket Number	506612000104

	272.	Shi, S.N. (1987) "Serum interferon in systemic lupus erythematosus" <i>Br. J. Dermatol.</i> 117:155-159.	
	273.	Shirali, G. S. et al. (2001) "Association of viral genome with graft loss in children after cardiac transplantation" <i>N. Engl. J. Med.</i> 344: 1498-503.	
	274.	Shoker, Ahmed et al. (2000) "Heightened CD40 Ligand Gene Expression in Peripheral CD4+ Cells from Patients with Kidney Allograft Rejection" <i>Transplantation</i> 70 (3): 497-505.	
	275.	Shulzhenko, Natalia et al. (2001) "Intragraft Activation of Genes Encoding Cytotoxic T Lymphocyte Effector Molecules Precedes the Histological Evidence of Rejection in Human Cardiac Transplantation" <i>Transplantation</i> 72 (10): 1705-1708.	
	276.	Shulzhenko, Natalia et al. (2001) "Monitoring of Intragraft and Peripheral Blood TIRC7 Expression as a Diagnostic Tool for Acute Cardiac Rejection in Humans" <i>Human Immunology</i> 62: 342-347.	
	277.	Staudt, L. M. and P. O. Brown. (2000) "Genomic Views of the Immune System" <i>Annu. Rev. Immunol.</i> 18: 829-859.	
	278.	Strehlau, Jurgen et al. (1997) "Quantitative detection of immune activation transcripts as a diagnostic tool in kidney transplantation" <i>Proc. Natl. Acad. Sci. USA</i> 94: 695-700.	
	279.	Tan, E. M. et al. (1982) "The 1982 revised criteria for the classification of systemic lupus erythematosus" <i>Arthritis Rheum.</i> 25: 1271-7.	
	280.	Tan, LamChin et al. (2001) "Sequential Monitoring of Peripheral T-Lymphocyte Cytokine Gene Expression in the Early Post Renal Allograft Period" <i>Transplantation</i> 71: 751-759.	
	281.	Toogood, Giles J. et al. (1996) "The Immune Response Following Small Bowel Transplantation" <i>Transplantation</i> 62 (6): 851-855.	
	282.	Törönen, Petri et al. (1999) "Analysis of gene expression data using self-organizing maps" <i>FEBS Letters</i> 451: 142-146.	
	283.	Torre-Amione, G. et al. (1996) "Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD)" <i>J. Am. Coll. Cardiol.</i> 27: 1201-6.	
	284.	Tsutamoto, T. et al. (2000) "Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure" <i>J. Am. Coll. Cardio.</i> 35: 714-21.	

Examiner Signature	/James Martinell/	Date Considered	03/13/2008
--------------------	-------------------	-----------------	------------

sf-1835832

Substitute for form 1449/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/511,937
<i>(Use as many sheets as necessary)</i>				Filing Date	April 24, 2003
				First Named Inventor	Jay WOHLGEMUTH
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	15	of	16	Attorney Docket Number	506612000104

285.	Tusher, Virginia Goss et al. (2001) "Significance analysis of microarrays applied to the ionizing radiation response" <i>PNAS</i> 98 (9) 5116-5121.	
286.	Umek, R. M. et al. (2001) "Electronic detection of nucleic acids: a versatile platform for molecular diagnostics" <i>J. Mol. Diagn.</i> 3: 74-84.	
287.	Vallin, H. (1999) "Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-alpha inducer in systemic lupus erythematosus" <i>J. Immunol.</i> 163: 6306-6313.	
288.	Vandevyver, Caroline et al. (1998) "Cytokine mRNA Profile of Myelin Basic Protein Reactive T-Cell Clones in Patients with Multiple Sclerosis" <i>Autoimmunity</i> 28: 77-89.	
289.	Vasconcellos, Lauro M. et al. (1998) "Cytotoxic Lymphocyte Gene Expression in Peripheral Blood Leukocytes Correlates with Rejecting Renal Allografts" <i>Transplantation</i> 66 (5): 562-566.	
290.	Vignali D. (2000) "Multiplexed particle-based flow cytometric assays" <i>J. Immun. Meth.</i> 243: 243-55.	
291.	Vincenti, F. et al. (2001) "Multicenter Trial Exploring Calcineurin Inhibitors Avoidance in Renal Transplantation" <i>Transplantation</i> 71 (9): 1282-1287.	
292.	Watanabe-Fukunaga, R. et al. (1992) "Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis" <i>Nature</i> 356: 314-317.	
293.	Welsh, J. B. et al. (2001) "Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer" <i>Proc. Natl. Acad. Sci. U.S.A.</i> 98: 1176-81.	
294.	Westin L. et al. (2000) "Anchored multiplex amplification on a microelectronic chip array" <i>Nat. Biotechnol.</i> 18: 199-204.	
295.	Whitehead, John. 2002. An Introduction to Logistic Regression. (web page: http://personal.ecu.edu/whiteheadj/data/logit/). 4/25/02: 63 pages.	
296.	Wu, J. et al. (1996) "Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease" <i>J. Clin. Invest.</i> 98: 1107-1113.	
297.	Xia, Dongyuan et al. (2001) "Real-Time Polymerase Chain Reaction Analysis Reveals an Evolution of Cytokine mRNA Production in Allograft Acceptor Mice" <i>Transplantation</i> 72 (5): 907-914.	

Examiner Signature	/James Martinell/	Date Considered	03/13/2008
--------------------	-------------------	-----------------	------------

sf- 1835832

Substitute for form 1449/PTO				<i>Complete if Known</i>	
				Application Number	10/511,937
				Filing Date	April 24, 2003
				First Named Inventor	Jay WOHLGEMUTH
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	16	of	16	Attorney Docket Number	506612000104

	298.	Yu et al. (2000) "Protein Synthesis-Dependent and Independent Induction of p69 2'-5'-Oligoadenylate Synthetase by Interferon- α ," <i>Cytokine</i> , 11(10): 744-750.	
	299.	Zhang, L. et al. (1997) "A New Interferon Regulatory Factor Associated with Epstein-Barr Virus Latency." <i>Molecular and Cellular Biology</i> , 17(10): 5748-5757.	
	300.	Zucker, S. et al. (1999) "Increased serum stromelysin-1 levels in systemic lupus erythematosus: lack of correlation with disease activity." <i>J Rheumatol.</i> 26 (1): 78-80.	


*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/James Martinelli/	Date Considered	03/13/2008
--------------------	--------------------	-----------------	------------

sf- 1835832

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JM/



08/16/07

11W 3700

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

		Application Number	10/511,937
		Filing Date	April 24, 2003
		First Named Inventor	Jay WOHLGEMUTH
		Art Unit	3700
		Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	5 + 5 Refs.	Attorney Docket Number	506612000104

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): <ol style="list-style-type: none"> 1. PTO/SB/08a/b (1 page) 2. 5 References 3. Return Receipt Postcard
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	
<input checked="" type="checkbox"/> Information Disclosure Statement (3 pages)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application	<input type="checkbox"/> Remarks	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53.		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	MORRISON & FOERSTER LLP (Customer No. 20872)		
Signature			
Printed name	Otis B. Littlefield		
Date	August 14, 2007	Reg. No.	48,751

I hereby certify that this paper is being deposited with the U.S. Postal Service via Express Mail Label No. EV513655195US to MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Dated: August 14, 2007

Signature: (Valerie Cohen)



I hereby certify that this paper is being deposited with the U.S. Postal Service via Express Mail Label No. EV513655195US to MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Dated: August 14, 2007 Signature: Valerie Cohen
(Valerie Cohen)

Patent
Docket No. 506612000104

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Jay WOHLGEMUTH et al.

Serial No.: 10/511,937

Filing Date: April 24, 2003

For: METHODS AND COMPOSITIONS FOR
DIAGNOSING AND
MONITORING TRANSPLANT
REJECTION

Examiner: Not Yet Assigned

Group Art Unit: 3700

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

This Supplemental Information Disclosure Statement is submitted:

- With the application; accordingly, no fee or separate requirements are required.
- Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.**
- After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - A fee is required. A check in the amount of __ is enclosed.
 - A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is believed to be due.
- After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of __ is enclosed.
 - A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)


Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 506612000104.

Dated: August 14, 2007

Respectfully submitted,

By 
Otis Littlefield

Registration No.: 48,751
MORRISON & FOERSTER LLP
425 Market Street
San Francisco, California 94105-2482
(415) 268-6846



Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/511,937
				Filing Date	April 24, 2003
				First Named Inventor	Jay WOHLGEMUTH
				Art Unit	3700
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	506612000104

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			
					T ⁶

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
1.	Alizadeh, A. A. et al. (2000). "Genomic-Scale Gene Expression Profiling of Normal and Malignant Immune Cells," <i>Current Opinion in Immunology</i> 12:219-225.				
2.	Glynne, R. et al. (2000). "B-Lymphocyte Quiescence, Tolerance and Activation as Viewed by Global Gene Expression Profiling on Microarrays," <i>Immunological Reviews</i> 176:216-246.				
3.	Glynne, R. J. et al. (2000). "Genomic-Scale Gene Expression Analysis of Lymphocyte Growth, Tolerance and Malignancy," <i>Current Opinion in Immunology</i> 12:210-214.				
4.	Marrack, P. et al. (2000). "Genomic-Scale Analysis of Gene Expression in Resting and Activated T Cells," <i>Current Opinion in Immunology</i> 12:208-209.				
5.	Supplemental Partial European Search Report mailed July 9, 2007, for EP Application No. 01997055.7 filed October 22, 2001, 6 pages.				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/James Martinelli/	Date Considered	03/13/2008
sf-2370336			

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JM/

NOV. 23. 2005 3:06PM

MOFO 28TH FL

RECEIVED
CENTRAL FAX CENTER

NO. 216 P. 1

NOV 23 2005



425 MARKET STREET
SAN FRANCISCO
CALIFORNIA 94105-2482
TELEPHONE: 415.268.7000
FACSIMILE: 415.268.7522
WWW.MOFO.COM

MORRISON & FOERSTER LLP
NEW YORK, SAN FRANCISCO,
LOS ANGELES, PALO ALTO,
SAN DIEGO, WASHINGTON, D.C.
DENVER, NORTHERN VIRGINIA,
ORANGE COUNTY, SACRAMENTO,
WALNUT CREEK, CENTURY CITY
TOKYO, LONDON, BEIJING,
SHANGHAI, HONG KONG,
SINGAPORE, BRUSSELS

NAME:	FACSIMILE:
MS Amendment U.S. Patent and Trademark Office	(571) 273-8300

FROM: Otis B. Littlefield,
Reg. No. 48,751

DATE: November 23, 2005

Number of pages with cover page:	9	
-------------------------------------	---	--

Preparer of this slip has confirmed that facsimile number given is 10586/lxt4
correct:

CAUTION - CONFIDENTIAL

This facsimile contains confidential information which may also be privileged. Unless you are the addressee (or authorized to receive for the addressee), you may not copy, use, or distribute it. If you have received it in error, please advise Morrison & Foerster LLP immediately by telephone or facsimile and return it promptly by mail.

ATTORNEY DOCKET NO.: 506612000104

SERIAL NO.: 10/511,937

FILING DATE: October 19, 2004

INVENTOR(S): Jay WOHLGEMUTH et al.

TITLE: METHODS AND COMPOSITIONS FOR DIAGNOSING AND
MONITORING TRANSPLANT REJECTION

EXAMINER: Not Yet Assigned

GROUP ART UNIT: Not Yet Assigned

Papers attached herewith:

1. Transmittal - 1 pg.
2. Information Disclosure Statement - 3 pgs.
3. PTO/SB/08a/b - 1 pg.
4. One Cited Reference - 3 pgs.

sf-2039713

NOV. 23. 2005 3:06PM MOFO 28TH FL

RECEIVED
CENTRAL FAX CENTER

NO. 216 P. 2

NOV 23 2005


PTO/SB/21 (09-04)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.


TRANSMITTAL FORM <i>(To be used for all correspondence after initial filing)</i>		Application Number 10/511,937
		Filing Date October 19, 2004
		First Named Inventor Jay WOHLGEMUTH
		Art Unit Not Yet Assigned
		Examiner Name Not Yet Assigned
Total Number of Pages in This Submission 8		Attorney Docket Number 506612000104

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement - 3 pgs. <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.58	<input type="checkbox"/> Drawing(s) (1 sheet) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD. Number of CD(s) <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1. PTO/SB/08a/b - 1 pg. 2. One Cited Reference - 3 pgs. 3. Fax Coversheet
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	MORRISON & FOERSTER LLP, Customer No. 20872		
Signature			
Printed name	Otis B. Littlefield		
Date	November 23, 2005	Reg. No.	48,751

I hereby certify that this correspondence is being facsimile transmitted to the Patent and Trademark Office to fax no. 671-273-8300, on the date shown below.

Dated: November 23, 2005

Signature: 

(Leura Tsang)

af-2039708

NOV. 23. 2005 3:06PM

MOFO 28TH FL


RECEIVED
CENTRAL FAX CENTER 216 P. 3

NOV 23 2005

I hereby certify that this correspondence is being facsimile transmitted to the Patent and Trademark Office to fax no. 571-273-8300, on the date shown below.

Dated: November 23, 2005

Signature:



Laura Tsang

Patent

Docket No. 506612000104

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Jay WOHLGEMUTH et al.

Examiner: Not Yet Assigned

Serial No.: 10/511,937

Group Art Unit: Not Yet Assigned

Filing Date: October 19, 2004

For: METHODS AND COMPOSITIONS FOR
DIAGNOSING AND MONITORING
TRANSPLANT REJECTION

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of foreign documents and non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

The documents listed on the attached Form PTO/SB/08a/b were cited in an INTERNATIONAL SEARCH REPORT mailed on September 23, 2005, directed to a counterpart international or foreign application and have not been previously cited. A certification under 37 C.F.R. § 1.97(e)(1) follows:

sf-2038309

Application No. 10/511,937
Supplemental Information Disclosure Statement

2

Docket No. 506612000104

I hereby certify that each item of information was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

This Supplemental Information Disclosure Statement is submitted:

- With the application; accordingly, no fee or separate requirements are required.
- Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - A fee is required. A check in the amount of __ is enclosed.
 - A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly, no fee is believed to be due.
- After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of __ is enclosed.
 - A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

sf-2038309

Application No. 10/511,937
Supplemental Information Disclosure Statement

3

Docket No. 506612000104

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing docket no. 506612000104.

Dated: November 23, 2005

Respectfully submitted,

By 
Otis B. Littlefield
Registration No.: 48,751
MORRISON & FOERSTER LLP
425 Market Street
San Francisco, California 94105-2482
(415) 268-6846

sf-2038309

NOV. 23. 2005 3:07PM

MOFO 28TH FL

RECEIVED
CENTRAL FAX CENTER

NO. 216 P. 6

NOV 23 2005

ALTERNATIVE TO PTO/SB/08a/b (07-05)

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/511,937
(Use as many sheets as necessary)				Filing Date	October 19, 2004
Sheet	1	of	1	First Named Inventor	Jay WOHLGEMUTH
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	506612000104

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
1.		US-5,120,525	06-09-1992	Goldenberg	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number-Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
					T ⁴

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP §109. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinda Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbol as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
2.		International Search Report mailed September 23, 2005, for PCT application no. PCT/US03/12946, filed April 24, 2003, 3 pages			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature sf-2038315	/James Martinell/	Date Considered	03/13/2008
----------------------------------	-------------------	-----------------	------------

PAGE 6/9 * RCVD AT 11/23/2005 6:06:13 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-6/30 * DNI:2738300 * CSID:415 2687522 * DURATION (mm:ss):03:44

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JM/